We then used an in vitro system based on the colon cancer cell line HCT116, genetically manipulated to express high levels of functionally active MR, to test the hypothesis that MR activation by agonists may negatively regulate tumor angiogenesis. This evidence concerns the gene NR3C2 and neoplasm.